Photobiomodulation (light therapy) for amnestic mild cognitive impairment (aMCI)

What is the study about?

This study is looking at using a form of non-invasive light therapy called photobiomodulation as a treatment for amnestic Mild Cognitive Impairment (aMCI), which is an early stage of Alzheimer’s disease. The study will look at the effect of the light therapy on your thinking abilities, quality of life, and the powerhouse of cells (the mitochondria).

 

Eligibility- Who can participate?

Participants must:

• Be 50 years of age or older
• Have a diagnosis of Mild Cognitive Impairment (MCI)

 

Time requirement

The entire study can take 10 to 12 weeks, and consist of:

 

• Screening visit to assess eligibility
• Baseline visit (2-3 sessions) to complete cognitive testing, blood test, and brain MRI/MRS
• At home treatments for 20 minutes per day, 6 days a week, for 6 weeks
• Post treatment visit (2-3 sessions) to complete the same tasks as the baseline visit

 

TDRA study investigator

Dr. Corinne Fischer, Dr. Tom Schweizer

 

More information

https://clinicaltrials.gov/ct2/show/NCT05563298

 

Video
Advances in Dementia Research Webinar- Listen to Dr. Neda Rashidi-Ranjbar discuss this  study in further detail: https://youtu.be/6kyrV0aBkR0

TDRA Site:

St. Michael’s Hospital,

Address: 209 Victoria St, Toronto, ON M5B 1T8

Age Group:

50 - 54, 55 - 59, 60 - 64, 65 - 69, 70 - 80, 81 - 85, 86 - 90, 91+

Target Population:

Mild cognitive impairment